



February 8, 2024

Revision of Dividend Forecast

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter “Santen”) announced that its Board of Directors resolved today to revise its dividend forecast for the fiscal year ending March 31, 2024.

1. Reason for Dividend Change

Santen considers returning profits to shareholders as its top management priority. As outlined in the medium-term management plan, Santen has a progressive dividend policy which consists of increasing dividends as a function of profit growth.

Taking into consideration its completion of structural reforms as well as medium to long term prospects concerning its financial situation, Santen decided to revise its fiscal year-end dividend forecast to 17 yen, an increase of 1 yen per share from its previous forecast of 16 yen. As a result, total annual dividends will be 33 yen per share for the year ending March 31, 2024.

2. Details of FY2023 Dividend Change (Year Ending March 31, 2024)

	Annual dividends (yen)		
	Interim	Year-end	Total
FY2023: Previously forecast (May 11,2023)	-	16.00	32.00
FY2023: Revised forecast	-	17.00	33.00
FY2023: Actual	16.00	-	-
FY2022: Actual (year ended March 31, 2023)	16.00	16.00	32.00

Contact:

Guillaume Sakuma

Global Head of IR, IR Group

E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “*Tenki ni sanyo suru*,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient’s perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”

For more information, please visit Santen’s website <https://www.santen.com/en>.